Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Clinics at Kakaako
2680
mi
from 98109
Honolulu, HI
NP001, Alzheimer's Disease, and Blood Markers of Inflammation
Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Clinics at Kakaako
2680
mi
from 98109
Honolulu, HI
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ATP Clinical Research, Inc.
991
mi
from 98109
Costa Mesa, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ATP Clinical Research, Inc.
991
mi
from 98109
Costa Mesa, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Synergy Research Centers
1065
mi
from 98109
Lemon Grove, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Synergy Research Centers
1065
mi
from 98109
Lemon Grove, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Collaborative Neuroscience
982
mi
from 98109
Long Beach, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Collaborative Neuroscience
982
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Irvine Center for Clinical Research
994
mi
from 98109
Irvine, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Irvine Center for Clinical Research
994
mi
from 98109
Irvine, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alliance Research
982
mi
from 98109
Long Beach, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alliance Research
982
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Syrentis Clinical Research
987
mi
from 98109
Santa Ana, CA
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
987
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
2279
mi
from 98109
Winston-Salem, NC
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Syrentis Clinical Research
987
mi
from 98109
Santa Ana, CA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Syrentis Clinical Research
987
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
2702
mi
from 98109
Delray Beach, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
2702
mi
from 98109
Delray Beach, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
The Memory Clinic
2372
mi
from 98109
Bennington, VT
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
The Memory Clinic
2372
mi
from 98109
Bennington, VT
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Bioclinica (Compass Research)
2547
mi
from 98109
Orlando, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Bioclinica (Compass Research)
2547
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
1063
mi
from 98109
San Diego, CA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
1063
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Axiom Clinical Research
2525
mi
from 98109
Tampa, FL
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Axiom Clinical Research
2525
mi
from 98109
Tampa, FL
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Boston Center for Memory
2479
mi
from 98109
Newton, MA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Boston Center for Memory
2479
mi
from 98109
Newton, MA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
PMG Research Inc.
2272
mi
from 98109
Winston-Salem, NC
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
PMG Research Inc.
2272
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
2369
mi
from 98109
Willow Grove, PA
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
2369
mi
from 98109
Willow Grove, PA
Click here to add this to my saved trials
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated:  12/31/1969
Toronto Memory Program
2064
mi
from 98109
Toronto,
Tau Screening Study in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Status: Enrolling
Updated: 12/31/1969
Toronto Memory Program
2064
mi
from 98109
Toronto,
Click here to add this to my saved trials
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects
Status: Enrolling
Updated:  12/31/1969
Molecular Neuroimaging, LLC
2432
mi
from 98109
New Haven, CT
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects
Status: Enrolling
Updated: 12/31/1969
Molecular Neuroimaging, LLC
2432
mi
from 98109
New Haven, CT
Click here to add this to my saved trials
Detecting an Early Response to Donepezil With Measures of Visual Attention
Detecting an Early Response to Donepezil With Measures of Visual Attention
Status: Enrolling
Updated:  12/31/1969
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Detecting an Early Response to Donepezil With Measures of Visual Attention
Detecting an Early Response to Donepezil With Measures of Visual Attention
Status: Enrolling
Updated: 12/31/1969
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Click here to add this to my saved trials
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Health
2275
mi
from 98109
Winston-Salem, NC
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Health
2275
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Caring for the Caregiver Network
A Tailored Technology Intervention for Diverse Caregivers of AD Patients
Status: Enrolling
Updated:  12/31/1969
University of Miami Miller School of Medicine
2730
mi
from 98109
Miami, FL
Caring for the Caregiver Network
A Tailored Technology Intervention for Diverse Caregivers of AD Patients
Status: Enrolling
Updated: 12/31/1969
University of Miami Miller School of Medicine
2730
mi
from 98109
Miami, FL
Click here to add this to my saved trials
The Brain Ketone Body Challenge Imaging Study
The Brain Ketone Body Challenge Imaging Study
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
2279
mi
from 98109
Winston-Salem, NC
The Brain Ketone Body Challenge Imaging Study
The Brain Ketone Body Challenge Imaging Study
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
PET Imaging of Subjects Using 124I-PU-AD
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering
2401
mi
from 98109
New York, NY
PET Imaging of Subjects Using 124I-PU-AD
PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering
2401
mi
from 98109
New York, NY
Click here to add this to my saved trials
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
Examining the Impact of Photobiomodulation (PBM) on Brain Function in Dementia
Status: Enrolling
Updated:  12/31/1969
San Francisco Veterans Affairs Medical Center
680
mi
from 98109
San Francisco, CA
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
Examining the Impact of Photobiomodulation (PBM) on Brain Function in Dementia
Status: Enrolling
Updated: 12/31/1969
San Francisco Veterans Affairs Medical Center
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center
971
mi
from 98109
Downey, CA
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center
971
mi
from 98109
Downey, CA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
1026
mi
from 98109
Aurora, CO
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
1026
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Medstar Rehabilitation Hospital
2322
mi
from 98109
Washington,
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Medstar Rehabilitation Hospital
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Shirley Ryan AbilityLab
1733
mi
from 98109
Chicago, IL
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Shirley Ryan AbilityLab
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Marionjoy Rehabilitation Hospital
1710
mi
from 98109
Wheaton, IL
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Marionjoy Rehabilitation Hospital
1710
mi
from 98109
Wheaton, IL
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Kentucky Clinic
2005
mi
from 98109
Lexington, KY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Kentucky Clinic
2005
mi
from 98109
Lexington, KY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Boston Med Ctr
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
1931
mi
from 98109
Detroit, MI
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
1931
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian-Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian-Weill Cornell Medical Center
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Burke Medical Research Institute
2404
mi
from 98109
White Plains, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Burke Medical Research Institute
2404
mi
from 98109
White Plains, NY
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
2016
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
Helsinki University Central Hospital
4764
mi
from 98109
Helsinki,
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
Helsinki University Central Hospital
4764
mi
from 98109
Helsinki,
Click here to add this to my saved trials
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital - Columbia University Medical Center
2400
mi
from 98109
New York, NY
Videofluoroscopic Swallowing Study (VFSS)
A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital - Columbia University Medical Center
2400
mi
from 98109
New York, NY
Click here to add this to my saved trials
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Status: Enrolling
Updated:  12/31/1969
University of Iowa
1556
mi
from 98109
Iowa City, IA
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease
Status: Enrolling
Updated: 12/31/1969
University of Iowa
1556
mi
from 98109
Iowa City, IA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Anchor Neuroscience
2201
mi
from 98109
Pensacola, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Anchor Neuroscience
2201
mi
from 98109
Pensacola, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alliance Research
982
mi
from 98109
Long Beach, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alliance Research
982
mi
from 98109
Long Beach, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Southern California Research, LLC
940
mi
from 98109
Simi Valley, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Southern California Research, LLC
940
mi
from 98109
Simi Valley, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Dade Medical Research Institute
2725
mi
from 98109
Miami, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Dade Medical Research Institute
2725
mi
from 98109
Miami, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sensible Healthcare
2538
mi
from 98109
Ocoee, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sensible Healthcare
2538
mi
from 98109
Ocoee, FL
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Manhattan Behavioral Medicine, LLC
2402
mi
from 98109
New York, NY
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Manhattan Behavioral Medicine, LLC
2402
mi
from 98109
New York, NY
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
9
mi
from 98109
Seattle, WA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
9
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network
1063
mi
from 98109
San Diego, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network
1063
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
CiTrials
926
mi
from 98109
Santa Ana, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
CiTrials
926
mi
from 98109
Santa Ana, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Viking Clinical Research
1011
mi
from 98109
Temecula, CA
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Viking Clinical Research
1011
mi
from 98109
Temecula, CA
Click here to add this to my saved trials
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Progressive Medical Research
2538
mi
from 98109
Port Orange, FL
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Progressive Medical Research
2538
mi
from 98109
Port Orange, FL
Click here to add this to my saved trials